C. Dickson

TL;DR: Baricitinib, an orally administered JAK‐1/JAK‐2 inhibitor, as monotherapy or combined with methotrexate (MTX) compared to MTX monotherapy in patients with active rheumatoid arthritis who had received no or minimal conventional synthetic disease‐modifying antirheumatic drugs (DMARDs) and who were naive to biologic DMARDs is evaluated.

TL;DR: In this integrated analysis of patients with moderate to severe active RA with exposure up to 5.5 years, baricitinib has an acceptable safety profile in the context of demonstrated efficacy.

TL;DR: Patients treated with tabalumab had greater SRI-5 response rates in a serologically active subset and improvements in more stringent SRI cut-offs, SELENA-SLEDAI, Physician's Global Assessment, anti-double-stranded DNA antibodies, complement, total B cells and immunoglobulins.

TL;DR: Increased rates of treatment-emergent infections including HZ were observed in patients with RA treated with baricitinib, consistent with baricinib’s immunomodulatory mode of action.

TL;DR: In RA patients with an inadequate response to methotrexate, baricitinib provided greater and more rapid pain relief than adalimumab and placebo, and analyses suggest the relationship between inflammation and pain may be different for baricit inib and ad alimumab treatments.